keyword
MENU ▼
Read by QxMD icon Read
search

Joaquim bellmunt

keyword
https://www.readbyqxmd.com/read/28922341/-working-toward-understanding-oligo-and-polymetastatic-prostate-cancer
#1
Brian F Chapin, Joaquim Bellmunt
No abstract text is available yet for this article.
September 15, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28916369/antiangiogenesis-to-curb-urothelial-cancer
#2
Joaquim Bellmunt
No abstract text is available yet for this article.
September 12, 2017: Lancet
https://www.readbyqxmd.com/read/28899722/effect-of-nonurothelial-histologic-variants-on-the-outcomes-of-radical-cystectomy-for-nonmetastatic-muscle-invasive-urinary-bladder-cancer
#3
Malte W Vetterlein, Thomas Seisen, Jeffrey J Leow, Mark A Preston, Maxine Sun, David F Friedlander, Christian P Meyer, Felix K-H Chun, Stuart R Lipsitz, Mani Menon, Adam S Kibel, Joaquim Bellmunt, Toni K Choueiri, Quoc-Dien Trinh
INTRODUCTION: Knowledge of the comparative oncologic outcomes of histologic variants after radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) relies on small case series. We compared the effect of pure squamous cell carcinoma, adenocarcinoma, and neuroendocrine carcinoma compared with pure urothelial carcinoma (PUC) on overall survival (OS) and pathologic tumor, lymph node, and surgical margin status after RC. PATIENTS AND METHODS: Using the National Cancer Database, we retrospectively examined patients undergoing RC for MIBC from 2003 to 2011...
August 24, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28864222/upper-tract-urothelial-carcinomas-prognostic-factors-and-outcomes-in-patients-with-non-lymph-node-distant-metastasis
#4
Elena Sevillano, Lillian Werner, Dominick Bossé, Aly-Khan A Lalani, Stephanie A M Wankowicz, Guillermo de Velasco, Matthew Farina, Kevin Lundgren, Toni K Choueiri, Aranzazu González Del Alba, Joaquim Bellmunt
BACKGROUND: Upper tract urothelial carcinomas (UTUCs) are increasingly recognized as separate malignancies. Additional insight into clinical outcomes and key prognostic factors are needed. OBJECTIVES: To detail outcomes of patients with UTUCs recurring after radical nephroureterectomy (RNU) and to determine a risk score that predicts outcomes of patients with non-lymph node distant metastasis. DESIGN, SETTING, AND PARTICIPANTS: Chart review of all patients who had an extraurothelial recurrence after RNU for UTUC at Dana-Farber Cancer Institute between 2009 and 2014...
August 2, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28853615/radical-cystectomy-or-bladder-preservation-with-radiochemotherapy-in-elderly-patients-with-muscle-invasive-bladder-cancer-retrospective-international-study-of-cancers-of-the-urothelial-tract-risc-investigators
#5
Jihane Boustani, Aurélie Bertaut, Matthew D Galsky, Jonathan E Rosenberg, Joaquim Bellmunt, Thomas Powles, Federica Recine, Lauren C Harshman, Simon Chowdhury, Guenter Niegisch, Evan Y Yu, Sumanta K Pal, Ugo De Giorgi, Simon J Crabb, Matthieu Caubet, Loïc Balssa, Matthew I Milowsky, Sylvain Ladoire, Gilles Créhange
BACKGROUND: Radical cystectomy (RC) and radiochemotherapy (RCT) are curative options for muscle-invasive bladder cancer (MIBC). Optimal treatment strategy remains unclear in elderly patients. MATERIAL AND METHODS: Patients aged 80 years old and above with T2-T4aN0-2M0-Mx MIBC were identified in the Retrospective International Study of Cancers of the Urothelial Tract (RISC) database. Patients treated with RC were compared with those treated with RCT. The impact of surgery on overall survival (OS) was assessed using a Cox proportional hazard model...
August 30, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28837718/adjuvant-chemotherapy-vs-observation-for-patients-with-adverse-pathologic-features-at-radical-cystectomy-previously-treated-with-neoadjuvant-chemotherapy
#6
Thomas Seisen, Asha Jamzadeh, Jeffrey J Leow, Morgan Rouprêt, Alexander P Cole, Stuart R Lipsitz, Adam S Kibel, Paul L Nguyen, Maxine Sun, Mani Menon, Joaquim Bellmunt, Toni K Choueiri, Quoc-Dien Trinh
Importance: Despite existing evidence of a benefit associated with cisplatin-based adjuvant chemotherapy (AC) after radical cystectomy (RC) for chemotherapy-naive patients with pT3/T4 and/or pN+ urothelial carcinoma of the bladder (UCB), to our knowledge, no studies have addressed the effectiveness of AC in those who received neoadjuvant chemotherapy (NAC) before surgery. Objective: To assess the comparative effectiveness of AC vs observation for patients with pT3/T4 and/or pN+ UCB previously treated with NAC and RC...
August 24, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28815048/society-for-immunotherapy-of-cancer-consensus-statement-on-immunotherapy-for-the-treatment-of-bladder-carcinoma
#7
Ashish M Kamat, Joaquim Bellmunt, Matthew D Galsky, Badrinath R Konety, Donald L Lamm, David Langham, Cheryl T Lee, Matthew I Milowsky, Michael A O'Donnell, Peter H O'Donnell, Daniel P Petrylak, Padmanee Sharma, Eila C Skinner, Guru Sonpavde, John A Taylor, Prasanth Abraham, Jonathan E Rosenberg
The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-practice guidelines and consensus reports have been developed and strengthened based on data on the timing, dose, and duration of therapy from randomized clinical trials, as well as by critical evaluation of criteria for progression...
2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28807024/society-for-immunotherapy-of-cancer-consensus-statement-on-immunotherapy-for-the-treatment-of-bladder-carcinoma
#8
Ashish M Kamat, Joaquim Bellmunt, Matthew D Galsky, Badrinath R Konety, Donald L Lamm, David Langham, Cheryl T Lee, Matthew I Milowsky, Michael A O'Donnell, Peter H O'Donnell, Daniel P Petrylak, Padmanee Sharma, Eila C Skinner, Guru Sonpavde, John A Taylor, Prasanth Abraham, Jonathan E Rosenberg
The standard of care for most patients with non-muscle-invasive bladder cancer (NMIBC) is immunotherapy with intravesical Bacillus Calmette-Guérin (BCG), which activates the immune system to recognize and destroy malignant cells and has demonstrated durable clinical benefit. Urologic best-practice guidelines and consensus reports have been developed and strengthened based on data on the timing, dose, and duration of therapy from randomized clinical trials, as well as by critical evaluation of criteria for progression...
August 15, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28803034/variations-in-the-costs-of-radical-cystectomy-for-bladder-cancer-in-the-usa
#9
Jeffrey J Leow, Alexander P Cole, Thomas Seisen, Joaquim Bellmunt, Matthew Mossanen, Mani Menon, Mark A Preston, Toni K Choueiri, Adam S Kibel, Benjamin I Chung, Maxine Sun, Steven L Chang, Quoc-Dien Trinh
BACKGROUND: Radical cystectomy (RC) for muscle-invasive bladder cancer (BCa) has potential for serious complications, prolonged length of stay and readmissions-all of which may increase costs. Although variations in outcomes are well described, less is known about determinants driving variation in costs. OBJECTIVE: To assess surgeon- and hospital-level variations in costs and predictors of high- and low-cost RC. DESIGN, SETTING, AND PARTICIPANTS: Cohort study of 23 173 patients who underwent RC for BCa in 208 hospitals in the USA from 2003 to 2015 in the Premier Healthcare Database...
August 9, 2017: European Urology
https://www.readbyqxmd.com/read/28761748/new-treatment-options-for-metastatic-renal-cell-carcinoma
#10
REVIEW
Alejo Rodriguez-Vida, Thomas E Hutson, Joaquim Bellmunt, Michiel H Strijbos
During the last decade, the treatment of advanced or metastatic renal cell carcinoma (RCC) was revolutionised with the advent of antiangiogenic drugs and tyrosine-kinase inhibitors. Several agents targeting the vascular endothelial growth factor (VEGF) pathway (sunitinib, bevacizumab, pazopanib, axitinib) or the mammalian target of rapamycin pathway (temsirolimus, everolimus) were since then progressively approved for first-line or later-line use in the treatment of patients with advanced RCC and became the new standard of care...
2017: ESMO Open
https://www.readbyqxmd.com/read/28757301/quality-of-life-outcomes-after-primary-treatment-for-clinically-localised-prostate-cancer-a-systematic-review
#11
REVIEW
Michael Lardas, Matthew Liew, Roderick C van den Bergh, Maria De Santis, Joaquim Bellmunt, Thomas Van den Broeck, Philip Cornford, Marcus G Cumberbatch, Nicola Fossati, Tobias Gross, Ann M Henry, Michel Bolla, Erik Briers, Steven Joniau, Thomas B Lam, Malcolm D Mason, Nicolas Mottet, Henk G van der Poel, Olivier Rouvière, Ivo G Schoots, Thomas Wiegel, Peter-Paul M Willemse, Cathy Yuhong Yuan, Liam Bourke
CONTEXT: Current evidence-based management for clinically localised prostate cancer includes active surveillance, surgery, external beam radiotherapy (EBRT) and brachytherapy. The impact of these treatment modalities on quality of life (QoL) is uncertain. OBJECTIVE: To systematically review comparative studies investigating disease-specific QoL outcomes as assessed by validated cancer-specific patient-reported outcome measures with at least 1 yr of follow-up after primary treatment for clinically localised prostate cancer...
July 27, 2017: European Urology
https://www.readbyqxmd.com/read/28753897/lack-of-effectiveness-of-postchemotherapy-lymphadenectomy-in-bladder-cancer-patients-with-clinical-evidence-of-metastatic-pelvic-or-retroperitoneal-lymph-nodes-only-a-propensity-score-based-analysis
#12
Andrea Necchi, Luigi Mariani, Salvatore Lo Vullo, Evan Y Yu, Michael E Woods, Yu-Ning Wong, Lauren C Harshman, Ajjaj Alva, Cora N Sternberg, Aristotelis Bamias, Petros Grivas, Vadim S Koshkin, Florian Roghmann, Jakub Dobruch, Bernie J Eigl, Lucia Nappi, Matthew I Milowsky, Guenter Niegisch, Sumanta K Pal, Ugo De Giorgi, Federica Recine, Ulka Vaishampayan, Dominik D Berthold, Daniel W Bowles, Jack Baniel, Christine Theodore, Sylvain Ladoire, Sandy Srinivas, Neeraj Agarwal, Simon Crabb, Srikala Sridhar, Ali-Reza Golshayan, Carsten Ohlmann, Evanguelos Xylinas, Thomas Powles, Johnathan E Rosenberg, Joaquim Bellmunt, Bas van Rhijn, Matthew D Galsky, Kees Hendricksen
BACKGROUND: Limited data is available on the role, and extent of, postchemotherapy lymphadenectomy (PC-LND) in patients with clinical evidence of pelvic (cN1-3) or retroperitoneal (RP) lymph node spread from urothelial bladder carcinoma. OBJECTIVE: To compare the outcomes of operated versus nonoperated patients after first-line chemotherapy. DESIGN, SETTING, AND PARTICIPANTS: Data from 34 centers was collected, totaling 522 patients, treated between January 2000 and June 2015...
June 3, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28753879/robot-assisted-versus-open-radical-cystectomy-in-patients-receiving-perioperative-chemotherapy-for-muscle-invasive-bladder-cancer-the-oncologist-s-perspective-from-a-multicentre-study
#13
Andrea Necchi, Gregory R Pond, Marc C Smaldone, Sumanta K Pal, Kevin Chan, Yu-Ning Wong, Rosalia Viterbo, Guru Sonpavde, Lauren C Harshman, Simon Crabb, Ajjai Alva, Simon Chowdhury, Ugo De Giorgi, Sandy Srinivas, Neeraj Agarwal, Aristotelis Bamias, Jack Baniel, Ali-Reza Golshayan, Sylvain Ladoire, Cora N Sternberg, Linda Cerbone, Evan Y Yu, Joaquim Bellmunt, Ulka Vaishampayan, Gunter Niegisch, Syed Hussain, Daniel W Bowles, Rafael Morales-Barrera, Matthew I Milowsky, Christine Theodore, Dominik R Berthold, Srikala S Sridhar, Thomas Powles, Jonathan E Rosenberg, Matthew D Galsky
BACKGROUND: Little is known about the outcomes of robot-assisted radical cystectomy (RARC) compared to open radical cystectomy (ORC) combined with perioperative chemotherapy for muscle-invasive urothelial bladder cancer (UBC). OBJECTIVE: To evaluate surgical and oncological outcomes for RARC and ORC in multimodal treatment. DESIGN, SETTING, AND PARTICIPANTS: Data from 28 centres were collected for cystectomies performed between January 2000 and July 2013...
March 31, 2017: European Urology Focus
https://www.readbyqxmd.com/read/28743155/neoadjuvant-chemotherapy-prior-to-radical-cystectomy-for-muscle-invasive-bladder-cancer-with-variant-histology
#14
Malte W Vetterlein, Stephanie A M Wankowicz, Thomas Seisen, Richard Lander, Björn Löppenberg, Felix K-H Chun, Mani Menon, Maxine Sun, Justine A Barletta, Toni K Choueiri, Joaquim Bellmunt, Quoc-Dien Trinh, Mark A Preston
BACKGROUND: Neoadjuvant chemotherapy in pure urothelial bladder cancer provides a significant survival benefit. However, to the authors' knowledge, it is unknown whether this benefit persists in histological variants. The objective of the current study was to assess the effect of neoadjuvant chemotherapy on the probability of non-organ-confined disease and overall survival after radical cystectomy (RC) in patients with histological variants. METHODS: Querying the National Cancer Data Base, the authors identified 2018 patients with histological variants who were undergoing RC for bladder cancer between 2003 and 2012...
July 25, 2017: Cancer
https://www.readbyqxmd.com/read/28690523/a-case-report-demonstrating-the-potential-clinical-benefit-of-exhaustive-molecular-profiling-in-an-aggressive-muscle-invasive-high-grade-metastatic-urothelial-carcinoma
#15
Amaya Ramírez de Olano, Joaquim Bellmunt, Ana Rodrigo, Luis Álvarez, Adriana Terrádez, Jesús García-Foncillas, Jean-François Laes
We present a muscle-invasive high-grade metastatic urothelial carcinoma patient, aged 71 years, with rapid progression from the diagnosis and a poor prognosis after 3 lines of treatment. A clinical exhaustive genomic profile was performed with the goal of finding potential actionable molecular alterations. The patient showed significant symptomatic and laboratory improvement with a nonstandard chemotherapy combination treatment identified by the molecular profiling, which would otherwise not have been considered...
May 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28591526/pembrolizumab-for-advanced-urothelial-carcinoma
#16
LETTER
Joaquim Bellmunt, Dean F Bajorin
New England Journal of Medicine, Volume 376, Issue 23, Page 2302-2304, June 2017.
June 8, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/28493171/immunotherapy-in-urothelial-cancer-recent-results-and-future-perspectives
#17
REVIEW
Matthew S Farina, Kevin T Lundgren, Joaquim Bellmunt
Cytotoxic chemotherapy has been the only systemic treatment of locally advanced and metastatic urothelial carcinoma for decades. Long-term survival remains stagnant around 12-14 months for patients with advanced disease who have progressed on or recurred after receiving first-line platinum-based chemotherapy. Improving clinical outcomes for patients with urothelial carcinoma in all disease settings requires the development of novel treatments, especially for patients who failed on first-line chemotherapy. Since the discovery of intravesical Bacillus-Calmette Guerin (BCG) in the 1970s for non-muscle invasive disease, there have not been any major breakthrough drugs that exploit the immune-sensitivity of bladder cancer until recently...
July 2017: Drugs
https://www.readbyqxmd.com/read/28487100/differential-expression-of-pd-l1-in-high-grade-t1-vs-muscle-invasive-bladder-carcinoma-and-its-prognostic-implications
#18
Stephanie A M Wankowicz, Lillian Werner, Anna Orsola, Jesse Novak, Michaela Bowden, Toni K Choueiri, Inés de Torres, Juan Morote, Gordon J Freeman, Sabina Signoretti, Joaquim Bellmunt
PURPOSE: PD-L1 is expressed on tumor cells and tumor immune cell infiltrates. In metastatic bladder cancer increased tumor immune cell infiltrate PD-L1 positivity correlated with better overall survival. However, to our knowledge in high grade T1 bladder tumors positivity on tumor cells and tumor immune cell infiltrates, and correlation with outcomes or pathological features remain unknown. MATERIALS AND METHODS: Formalin fixed, paraffin embedded tumor samples from 140 patients with clinically annotated, high grade T1 bladder tumors were retrieved...
May 6, 2017: Journal of Urology
https://www.readbyqxmd.com/read/28478885/from-the-uncertainties-to-the-evidence-a-brief-history-of-immunotherapy-as-salvage-therapy-for-advanced-bladder-cancer-through-a-meta-analysis
#19
Andrea Necchi, Daniele Raggi, Patrizia Giannatempo, Guru Sonpavde, Matthew D Galsky, Joaquim Bellmunt, Luigi Mariani, Rosalba Miceli
No abstract text is available yet for this article.
April 13, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28412065/comparative-effectiveness-of-trimodal-therapy-versus-radical-cystectomy-for-localized-muscle-invasive-urothelial-carcinoma-of-the-bladder
#20
Thomas Seisen, Maxine Sun, Stuart R Lipsitz, Firas Abdollah, Jeffrey J Leow, Mani Menon, Mark A Preston, Lauren C Harshman, Adam S Kibel, Paul L Nguyen, Joaquim Bellmunt, Toni K Choueiri, Quoc-Dien Trinh
Given the lack of randomized evidence comparing trimodal therapy (TMT) to radical cystectomy (RC) for muscle-invasive urothelial carcinoma of the bladder (UCB), we performed an observational cohort study to examine the comparative effectiveness of these two definitive treatments. Within the National Cancer Data Base (2004-2011),we identified 1257 (9.8%) and 11 586 (90.2%) patients who received TMT and RC, respectively. Inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier analysis showed that median overall survival (OS) was similar between the TMT (40 mo, 95% confidence interval [CI] 34-46) and RC groups (43 mo 95% CI 41-45; p=0...
April 12, 2017: European Urology
keyword
keyword
22154
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"